ROSEN, A PROSPECTIVE LAW FIRM, Urges Applied Therapeutics, Inc. Investors to Secure Advice Before Important Securities Class Action Deadline



New York, New York–(Newsfile Corp. – January 11, 2025) – WHY: The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. the important thing February 18, 2025 leads the plaintiff’s deadline.

WHATEVER: If you purchase Applied Therapeutics securities during the Class Period you may be entitled to compensation free of any out-of-pocket fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Applied Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=32500 or call Phillip Kim, Esq. toll free at 866-767-3653 or email [email protected] for class action information. A class action lawsuit has been filed. If you want to serve as the lead plaintiff, you must move the Court no later than February 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in the conduct of litigation.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, the companies issuing the notices don’t have the same experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen who refer clients or partners to the law firms that actually litigate the cases. Be wise in choosing advice. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and shareholder derivative litigation. The Rosen Law Firm achieved the largest securities class action settlement against a Chinese Company at that time. The Rosen Law Firm is ranked No. 1 in the ISS Securities Class action (WA:) Services for the number of securities class action settlements in 2017. The company has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the company earned over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the statements made during the class were false and/or materially misleading because they concealed and misrepresented the clinical trial protocols and procedures established by Applied Therapeutics. Therefore, the defendants gave investors the false impression that the protocol and good clinical practices were followed properly. The lawsuit alleges that, in fact, Applied Therapeutics did not follow the trial protocol and good clinical practices which, in turn, created an even greater risk that the trial data would be rejected by the US Food and Drug Administration. Administration (“FDA”) in the context of a New Drug Application. When the true details entered the market, the lawsuit claims that investors suffered damage.

To participate in the Applied Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=32500 call Phillip Kim, Esq. toll free at 866-767-3653 or email [email protected] for class action information.

No Class Verified. Until a class is certified, you are not represented by counsel unless you hold one. You can choose the advice you want. You can also stay out of class and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent on serving as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https :// /www.facebook.com/rosenlawfirm.

Attorney Advertising. The first results do not guarantee a similar result.

—————————-

Contact information:

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236844





Source link

  • Related Posts

    Baby boomers and ‘Ozempic face’ fuel injectables preference

    Unlock Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favorite stories in this weekly newsletter. Baby boomers and users of weight-loss drugs suffering from “facial sagging”…

    China’s central bank governor Pan meets with Bailey at the BOE in Beijing By Reuters

    SHANGHAI (Reuters) – People’s Bank of China Governor Pan Gongsheng met his Bank of England counterpart, Andrew Bailey, on Saturday in Beijing and discussed topics including financial stability and cooperation,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *